Skip to Content

Scorpion Protein Illuminates Brain Tumors for Surgeons

A compound derived from a toxin from scorpion venom could help neurosurgeons differentiate between healthy and cancerous brain tissue.
December 17, 2012

Jim Olson, a pediatric neuro-oncologist at Seattle Children’s Hospital, was reviewing with his colleagues the case of a 17-year-old girl several years ago who had just undergone brain surgery to remove a tumor. An MRI scan revealed a thumb-size piece of tumor left behind. In the operating room, the tumor tissue had looked just like healthy brain tissue. During the review meeting, the hospitals’ chief of neurosurgery turned to Olson and said: “Jim, you have to come up with a way to light these cells up.”

So Olson and a neurosurgical resident started searching for a way to highlight cancer cells in the operating room. Eventually, they came across a report of a scorpion toxin that binds to brain tumors but not healthy cells. By linking a synthetic version of this protein to a molecule that glows in near-infrared light, the researchers think they may have found what they call “tumor paint.”

In their very first test, the pair injected the compound into the tail vein of a mouse whose body harbored a transplanted human tumor. “Within 15 to 20 minutes, the tumor started to glow, bright and distinct from the rest of the mouse,” says Olson.

A Seattle company called Blaze Bioscience has licensed the technology from the Fred Hutchinson Cancer Center. Olson says human trials will begin late in 2013.

The scorpion toxin is special not only because it binds to tumor cells, but because it can cross the blood-brain barrier—a cellular and molecular fortification that lines blood vessels in the brain and prevents most compounds from entering.

“Usually, peptides don’t get into the brain unless they bind to something specific that carries it in there,” says Harald Sontheimer, a neurobiologist at the University of Alabama in Birmingham, who first identified the neurological potential of the scorpion protein.

Although derived from venom, the toxin seems to be safe. A biotech company started by Sontheimer showed in early clinical trials that a version of the scorpion toxin tagged with radioactive iodine was safe in patients. However, the company closed before late-stage testing of the iodine-tagged compound, which is now owned by Japanese pharmaceutical company Eisai.

The tumor paint developed by Olson may also light up cancer outside of the brain. Animal studies suggest it could also demarcate prostate, colon, breast, and other tumors. The potential the compound has to save healthy brain tissue and improve patients’ lives is told in a short film called Bringing Light, which is in the running for the Sundance Film Festival. 

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.